People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
University of Bristol has been crowned ‘AI University of The Year ... areas such as healthcare and robotics are expected to benefit hugely, and automated drug discovery and climate research should be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback